Share Market Newspaper

Invasive Pneumococcal Disease Market to Grow Substantially During the Forecast Period (2019-32) – DelveInsight | Key Companies – Vaxcyte (VAX-24), Pfizer (PF-06482077), Merck, Afinivax, Eubiologics

 Breaking News
  • No posts were found

Invasive Pneumococcal Disease Market to Grow Substantially During the Forecast Period (2019-32) – DelveInsight | Key Companies – Vaxcyte (VAX-24), Pfizer (PF-06482077), Merck, Afinivax, Eubiologics

January 17
17:06 2023
Invasive Pneumococcal Disease Market to Grow Substantially During the Forecast Period (2019-32) - DelveInsight | Key Companies - Vaxcyte (VAX-24), Pfizer (PF-06482077), Merck, Afinivax, Eubiologics
Delveinsight Business Research LLP
The Invasive Pneumococcal Disease Market is anticipated to grow in the coming years owing to the entry of broad-coverage vaccines in a market with a huge at-risk population and extensive research and development activities of pharmaceutical companies.

DelveInsight’s “Invasive Pneumococcal Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Invasive Pneumococcal Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Invasive Pneumococcal Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Invasive Pneumococcal Disease Market

Invasive Pneumococcal Disease: An Overview

According to European Centre for Disease Prevention and Control (ECDC), pneumococcal diseases are symptomatic infections caused by the bacterium Streptococcus pneumoniae (S. pneumoniae), commonly referred to as pneumococci. The term Invasive Pneumococcal Disease is used for more severe and invasive pneumococcal infections, such as bacteremia, sepsis, meningitis, and osteomyelitis.

Improved diagnostic techniques and more efficacious treatments may help reduce the burden of pneumococcal disease, but preventive measures, such as influenza and pneumococcal vaccination, should be promoted to avoid preventable diseases, particularly in the elderly.

Treatment includes antibiotic therapy for symptomatic patients. Symptomatic treatment for patients in most geographies is by “Infectious Disease – Clinical Practice Guidelines,” prescribed by respective health organizations like CDC(US), NICE(UK), ECDPC(EU), etc.,

Invasive Pneumococcal Disease Market Key Facts

  • The Invasive Pneumococcal Disease market size in the seven major markets was USD 6,561.9 million in 2020, which is anticipated to grow by 2032.

  • The total number of incident cases of Invasive Pneumococcal Disease in the 7MM countries was 55,000+ in 2020.

  • Pneumococcal pneumonia causes an estimated 150,000 hospitalizations each year in the United States. Pneumococcal meningitis and bacteremia killed approximately 3,500 people in the United States in 2018.

  • Pneumococcal infections and IPDs are major causes of communicable disease morbidity and mortality in Europe and globally, with the highest burden of disease found in young children and the elderly.

  • There are at least 90 strains of S. pneumonia, and no vaccine can protect against them all. However, vaccines can help prevent infection by the most common strains of bacteria. 

  • Companies all over the globe are persistently working towards the development of new treatment therapies for Invasive Pneumococcal Disease. There are several drugs in the pipeline, some of which include PF-06482077 by Pfizer, ASP3772 by Afinivax, V114 by Merck, VAX24 by Vaxcyte, EuPCV by eubiologics, among others.

Invasive Pneumococcal Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Invasive Pneumococcal Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Invasive Pneumococcal Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Invasive Pneumococcal Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Invasive Pneumococcal Disease Epidemiology, Segmented by –

  • Incidence cases of Pneumococcal Disease in the 7MM (2019–2032)

  • Incident-cases of Invasive pneumococcal disease (IPD) in the 7MM (2019–2032)

  • Age-specific cases of Invasive pneumococcal disease (IPD) in the 7MM (2019–2032)

Invasive Pneumococcal Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Invasive Pneumococcal Disease market or expected to be launched during the study period. The analysis covers the Invasive Pneumococcal Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Invasive Pneumococcal Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Invasive Pneumococcal Disease Market Will Evolve and Grow by 2032 @

Invasive Pneumococcal Disease Therapeutics Market

There are several novel therapies in the pipeline that will help improve the Invasive Pneumococcal Disease treatment scenario, address the current unmet needs of patients and drive the market in the future. 

The Leading Companies in the Invasive Pneumococcal Disease Therapeutics Market Include:

  • Pfizer

  • Merck

  • Wyeth Pharmaceuticals

  • GlaxoSmithKline

  • Merck Sharp & Dohme Corp

  • Affinivax

  • Astellas Pharma

  • Vaxcyte

  • ImmunoBiology Ltd.

  • Merck Sharp & Dohme Corp

  • EuBiologics

And Many Others

Invasive Pneumococcal Disease Drugs Covered in the Report Include:

  • V114: Merck Sharp & Dohme Corp

  • PF-06482077: Pfizer

  • ASP3772: Afinivax

  • VAX24: Vaxcyte

  • EuPCV: Eubiologics

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Invasive Pneumococcal Disease Competitive Intelligence Analysis

4. Invasive Pneumococcal Disease Market Overview at a Glance

5. Invasive Pneumococcal Disease Disease Background and Overview

6. Invasive Pneumococcal Disease Patient Journey

7. Invasive Pneumococcal Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Invasive Pneumococcal Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Invasive Pneumococcal Disease Unmet Needs

10. Key Endpoints of Invasive Pneumococcal Disease Treatment

11. Invasive Pneumococcal Disease Marketed Products

12. Invasive Pneumococcal Disease Emerging Drugs and Latest Therapeutic Advances

13. Invasive Pneumococcal Disease Seven Major Market Analysis

14. Attribute Analysis

15. Invasive Pneumococcal Disease Market Outlook (In US, EU5, and Japan)

16. Invasive Pneumococcal Disease Access and Reimbursement Overview

17. KOL Views on the Invasive Pneumococcal Disease Market

18. Invasive Pneumococcal Disease Market Drivers

19. Invasive Pneumococcal Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Other Trending Healthcare Reports By DelveInsight

Interventional Radiology Devices Market

The global Interventional Radiology Devices Market is expected to grow at a CAGR of 5.23% during the forecast period of 2021-2027. The increase in demand for interventional radiology devices is primarily attributed to the increasing patient pool due to an increasing prevalence of chronic disorders & cancer and due to the increasing number of geriatric patients globally. Some of the leading companies in the Interventional Radiology Devices Market include General Electric, Koninklijke Philips N.V., Carestream Health, ESAOTE SPA, Hitachi, Hologic, Siemens Healthcare, CANON MEDICAL, Samsung Medison, Medtronic, Agfa-Gevaert Group, Teleflex, Cook, Analogic Corporation, Trivitron Healthcare, Stryker, Olympus, Toshiba Medical Systems, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States